Food stocks fell at the beginning of the day, and food stocks fell at the beginning, and food stocks fell at the beginning, and Jialong shares, Anji Food, Huang Shanghuang, three squirrels, and Barbie Foods followed suit.Zongheng Communication established a new science and technology company in Zhejiang. The enterprise search APP shows that recently, Zongheng Cross-border Technology (Zhejiang) Co., Ltd. was established with Xu Shasha as its legal representative and a registered capital of 10 million yuan. Its business scope includes: sales of information security equipment; Network equipment sales; Internet of things technical services, etc. Enterprise equity penetration shows that the company is wholly owned by Zongheng Communication.Domestic insurance in Hong Kong stocks and Chinese brokerage stocks fluctuated lower, while domestic insurance in Hong Kong stocks and Chinese brokerage stocks fluctuated lower. Guolian Securities fell more than 5%, followed by New China Life Insurance, China Pacific Insurance, China Life Insurance, China Merchants Securities and china galaxy.
Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)The retail sector continued its upward trend of Zhongbai Group for 10 days and 7 boards, and the retail sector continued its upward trend. Zhongbai Group for 10 days and 7 boards, Maoye Commercial and Actually Zhijia had daily limit, and Guangbai shares, Dashang shares, Central Shopping Mall and Hongqi Chain opened higher collectively.
The financing balance of the two cities increased by 6.856 billion yuan. As of December 12, the financing balance of the Shanghai Stock Exchange was 961.758 billion yuan, an increase of 2.592 billion yuan over the previous trading day. The financing balance of Shenzhen Stock Exchange was reported at 916.865 billion yuan, an increase of 4.264 billion yuan over the previous trading day; The two cities totaled 1,878.623 billion yuan, an increase of 6.856 billion yuan over the previous trading day.Look at the picture: The increased confidence of Japan's large-scale manufacturing industry indicates that the economic development is in line with the Bank of Japan's forecast. Before the Bank of Japan's policy meeting next week, the confidence of Japan's large-scale manufacturing industry has increased. According to the quarterly short-term report released by the Bank of Japan on Friday, the short-term survey index of Japan's large manufacturing industry rose slightly to 14 in December, with an estimated 13. The short-term survey index of large non-manufacturing industry decreased slightly from 34 to 33. Small businesses' confidence in manufacturing and service industries has also improved, although the outlook has slightly weakened or remained unchanged. The short-term report has attracted the attention of the Bank of Japan and is the last batch of major domestic data that will be carefully studied before the interest rate decision on December 19. This result shows that Japan's economic development is in line with the forecast of the Bank of Japan and is a condition for further interest rate hike. Compared with December, economists are more inclined to expect the Bank of Japan to take action in January next year, but still believe that the risk of raising interest rates next week is high.Chongda Technology: Five measures are taken to deal with the challenges and opportunities of industry development. Chongda Technology (002815) said in the online collective reception day of investors on December 12 that the company's measures to deal with the challenges and opportunities of industry development include: optimizing product structure, continuing to promote the optimization and upgrading of product structure, increasing R&D investment and market expansion in the field of high-end PCB boards, and accelerating the introduction of high-value customers and orders; Improve production efficiency and cost control; Accelerate the pace of capacity expansion, and promote the speed of capacity improvement of Dalian Plant, Zhuhai No.1 Plant and Zhuhai No.2 Plant in an orderly manner; According to market demand, adjust product price strategy in real time to improve profitability; Accelerate the construction of production base in Thailand, actively participate in international competition and cooperation, and enhance the company's visibility and influence in the global PCB market.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14